Conference Programme

Abstract Types

Oral abstract session

Poster exhibition

E-poster
Tracks

Track A – Basic science

Track B – Clinical science

Track C – Epidemiology and prevention science

Track D – Social and behavioural science

Track E – Implementation science, economics, systems and synergies

Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 study	Oral abstract session with live Q&A	HIV prevention research
Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents	Oral abstract session with live Q&A	Antiretroviral therapies and clinical issues in infants, children and adolescents
Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D	Oral abstract session with live Q&A	Antiretroviral therapies and clinical issues in adults
In vivo genome engineering of human T cells results in ART-free control of HIV-1 in humanized mice	Oral abstract session with live Q&A	Novel treatment and prevention strategies
Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV	Oral abstract session with live Q&A	Antiretroviral therapies and clinical issues in adults
Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in mice	Oral abstract session with live Q&A	SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies
Reporting, prevention and response of gender based violence against men who have sex with men in Taraba State, Nigeria	Oral abstract session with live Q&A	Social and behavioural aspects and approaches to HIV
COVID-19 vaccine effectiveness by HIV status and injection drug use history	Oral abstract session with live Q&A	Epidemiology of COVID-19
Gut memory CD4+ T cells from people with HIV on suppressive ART express high levels of intracellular HIV sensors	Oral abstract session with live Q&A	HIV pathogenesis
Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)	Oral abstract session with live Q&A	Clinical complications of HIV and antiretroviral therapy